IBALIZUMAB

540 reported adverse events

Drug classes: CD4-directed Blocking Antibody [EPC] Human Immunodeficiency Virus 1 Post-attachment Fusion Inhibitor [EPC]

These side effects are most commonly reported by patients taking IBALIZUMAB:

# Side effect Count
0 PRODUCT DOSE OMISSION ISSUE 45
1 VIRAL LOAD INCREASED 45
2 DRUG INEFFECTIVE 44
3 RASH 43
4 HOSPITALISATION 36
5 FATIGUE 30
6 OFF LABEL USE 30
7 DIARRHOEA 28
8 NAUSEA 26
9 DEATH 25
See all common reactions for IBALIZUMAB

IBALIZUMAB is most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 SOMATIC PAIN 1 0.2000
1 BLOOD HIV RNA 4 0.0769
2 CONGENITAL HIV INFECTION 2 0.0513
3 ANAL CANCER RECURRENT 1 0.0476
4 VULVAL CANCER STAGE 0 1 0.0179
5 PRODUCT USE IN UNAPPROVED THERAPEUTIC ENVIRONMENT 11 0.0126
6 T-LYMPHOCYTE COUNT DECREASED 8 0.0117
7 VIRAL LOAD INCREASED 45 0.0116
8 GENOTYPE DRUG RESISTANCE TEST POSITIVE 11 0.0107
9 MIDDLE CEREBRAL ARTERY STROKE 1 0.0088
See all enriched reactions for IBALIZUMAB